Salford Royal NHS Foundation Trust operated Salford Royal Hospital in Greater Manchester until 2017. Its chief executive is Raj Jain. In December 2017 it was announced that the Trust was to form a new healthcare organisation by combining with Pennine Acute Hospitals NHS Trust.

During the past decade, Salford Royal NHS Foundation Trust conducted 128 clinical trials. In the 10-year time frame, 128 clinical trials started and 39 clinical trials were completed, i.e. on average, 30.5% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 22 clinical trials were completed. i.e. 95.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Salford Royal NHS Foundation Trust" #1 sponsor was "University of Manchester" with 10 trials, followed by "Hoffmann-La Roche" with 9 trials sponsored, "BioMarin Pharmaceutical" with 6 trials sponsored, "Pfizer" with 5 trials sponsored and "University College, London" with 5 trials sponsored. Other sponsors include 140 different institutions and companies that sponsored additional 109 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Salford Royal NHS Foundation Trust" #1 collaborator was "Northern Care Alliance NHS Foundation Trust" with 7 trials as a collaborator, "National Institute for Health Research, United Kingdom" with 6 trials as a collaborator, "Cancer Research UK" with 4 trials as a collaborator, "NHS Lothian" with 4 trials as a collaborator and "Queen Mary University of London" with 4 trials as a collaborator. Other collaborators include 170 different institutions and companies that were collaborators in the rest 153 trials.

According to Clinical.Site data, the most researched conditions in "Salford Royal NHS Foundation Trust" are "Fabry Disease" (8 trials), "Psoriasis" (8 trials), "Acromegaly" (4 trials), "Pompe Disease" (4 trials) and "Atopic Dermatitis" (3 trials). Many other conditions were trialed in "Salford Royal NHS Foundation Trust" in a lesser frequency.

Most popular intervention types in "Salford Royal NHS Foundation Trust" are "Drug" (108 trials), "Other" (27 trials), "Biological" (16 trials), "Device" (11 trials) and "Procedure" (10 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "Ocrelizumab" (4 trials), "AT2221" (3 trials), "ATB200" (3 trials) and "BMN 701" (3 trials). Other intervention names were less common.

The vast majority of trials in "Salford Royal NHS Foundation Trust" are 172 trials for "All" genders, 5 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Salford Royal NHS Foundation Trust". undefined are not yet recruiting, 35 are recruiting, 26 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 84 completed trials in Salford Royal NHS Foundation Trust, undefined suspended trials, and 24 terminated clinical trials to date.

Out of the total trials that were conducted in Salford Royal NHS Foundation Trust, 8 "Phase 1" clinical trials were conducted, 37 "Phase 2" clinical trials and 77 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 29 trials that are defined as “Not Applicable".